The stock of Upstream Bio Inc (UPB) has seen a 16.38% increase in the past week, with a 18.44% gain in the past month, and a 42.90% flourish in the past quarter. The volatility ratio for the week is 8.22%, and the volatility levels for the past 30 days are at 5.08% for UPB. The simple moving average for the past 20 days is 17.84% for UPB’s stock, with a -22.46% simple moving average for the past 200 days.
Is It Worth Investing in Upstream Bio Inc (NASDAQ: UPB) Right Now?
Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for UPB is 19.37M and currently, short sellers hold a 19.34% of that float. On June 03, 2025, UPB’s average trading volume was 309.38K shares.
UPB) stock’s latest price update
Upstream Bio Inc (NASDAQ: UPB)’s stock price has soared by 15.49 in relation to previous closing price of 9.23. Nevertheless, the company has seen a gain of 16.38% in its stock price over the last five trading days. globenewswire.com reported 2025-05-20 that WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer.
Analysts’ Opinion of UPB
Piper Sandler gave a rating of “Overweight” to UPB, setting the target price at $75 in the report published on November 05th of the previous year.
UPB Trading at 29.35% from the 50-Day Moving Average
After a stumble in the market that brought UPB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.82% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at UPB starting from Chimovits Erez, who purchase 825,000 shares at the price of $17.00 back on Oct 15 ’24. After this action, Chimovits Erez now owns 4,554,873 shares of Upstream Bio Inc, valued at $14,025,000 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of Upstream Bio Inc, purchase 825,000 shares at $17.00 during a trade that took place back on Oct 15 ’24, which means that ORBIMED ADVISORS LLC is holding 4,554,873 shares at $14,025,000 based on the most recent closing price.
Stock Fundamentals for UPB
Current profitability levels for the company are sitting at:
- -41.27 for the present operating margin
- 1.0 for the gross margin
The net margin for Upstream Bio Inc stands at -34.49. The total capital return value is set at -0.21.
Based on Upstream Bio Inc (UPB), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -48.69.
Currently, EBITDA for the company is -77.67 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 219.44. The receivables turnover for the company is 1.32for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 47.43.
Conclusion
To wrap up, the performance of Upstream Bio Inc (UPB) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
